Skip to Main Content

Paper Details

Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia.
Nat Cancer
104
2020
AML, AZD5991, BCL2, BCL2 gene family, BCL2A1, CLEC7A, KRAS, MCL1, PTPN11, RNA, Venetoclax, acute myeloid leukemia, myelomonocytic leukemia, patient, patients, primary, venetoclax
Apoptosis, Biomarkers, Bridged Bicyclo Compounds, Heterocyclic, Cell Line, Tumor, Humans, Leukemia, Myeloid, Acute, Proto-Oncogene Proteins c-bcl-2, Sulfonamides
Author NameAffiliation
Haijiao ZhangOregon Health & Science University Knight Cancer Institute
Yusuke NakauchiCancer Institute, and Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine
Thomas K??hnkeCancer Institute, and Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine
Melissa StaffordCancer Institute, and Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine
Daniel BottomlyDepartment of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University Knight Cancer Institute
Rozario ThomasCancer Institute, and Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine
Beth WilmotDepartment of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University Knight Cancer Institute
Shannon K McWeeneyDepartment of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University Knight Cancer Institute
Ravindra MajetiCancer Institute, and Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine
Jeffrey W TynerOregon Health & Science University Knight Cancer Institute
  • 1 - 10

Datasets

Release 1.2